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Dendritic cells (DCs) are major players in the control of adaptive tolerance and immunity.
Therefore, their speciﬁc generation and adoptive transfer into patients or their in vivo target-
ing is attractive for clinical applications. While injections of mature immunogenic DCs are
tested in clinical trials, tolerogenic DCs still are awaiting this step. Besides the tolerogenic
potential of immature DCs, also semi-mature DCs can show tolerogenic activity but both
types also bear unfavorable features. Optimal tolerogenic DCs, their molecular tool bar,
and their use for speciﬁc diseases still have to be deﬁned. Here, the usefulness of in vitro
generated and adoptively transferred semi-mature DCs for tolerance induction is outlined.
The in vivo targeting of semi-mature DCs as represented by steady state migratory DCs
are discussed for treatment of autoimmune diseases and allergies. First clinical trials with
transcutaneous allergen application may point to their therapeutic use in the future.
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IMMATURE DCs
Tolerogenicity of dendritic cells (DCs) has been shown by many
experiments in vitro and in vivo (Manicassamy and Pulendran,
2011). There has been a debate whether certain subsets or the
maturation/activation state deﬁnes DC tolerogenicity. In mice, all
known lymphoid organ DC subsets have been demonstrated to
bear tolerogenic potential, as shown for CD4+ (Sato et al., 2003b;
Chung et al., 2005),CD8α+ (Belz et al., 2002; Ferguson et al., 2002;
Yamazaki et al., 2008), and plasmacytoid DC (pDC) subsets (Mar-
tin et al., 2002; Ochando et al., 2006; Hadeiba et al., 2008) but
also human monocyte-derived DCs (Sato et al., 2003a). Condi-
tional ablation of DCs during the steady state in mice results in a
loss of self-tolerance (Birnberg et al., 2008;Ohnmacht et al., 2009).
Experimental animal models in transplantation, autoimmunity or
allergy and indications from human studies suggest a tolerogenic
potential of immature DCs (Bluestone et al., 2007; Morelli and
Thomson, 2007; Hilkens et al., 2010; Manicassamy and Pulen-
dran, 2011). Human immature DCs, loaded with the inﬂuenza
matrix peptide and keyhole limpet hemocyanin and then injected
i.v. into healthy individuals induced tolerance (Dhodapkar et al.,
2001). Together, not a deﬁned DC subset or the presentation of
foreign antigens dictates DC tolerogenicity but their maturation
state.
In vivo most of tissue- and lymphoid organ-resident DCs are
immature (Wilson et al., 2003) but after ex vivo isolation they
lose their tolerogenic potential due to maturation induced by
the preparation procedure (Maldonado-López et al., 1999). Thus,
immature DCs need to acquire maturation resistance to subse-
quent stimuli to act strictly tolerogenic. This can be achieved
for in vitro generated DCs by speciﬁc conditioning to preserve
Abbreviations: APC, antigen-presenting cells; DCS, dendritic cells; Th1, T helper 1;
Th2, T helper 2; Th17, T helper 17; Tregs, regulatory T cells; Tr1, T regulatory type
1; TNF/DCS, TNF-matured DCS.
their immature state (Thomson, 2010). Alternatively, targeting of
immature DCs in vivo can be used to induce tolerance by tar-
geting certain surface receptors that mediate tolerance, such as
ﬁrst demonstrated for the 33D1 (DCIR2) antibody binding to
the CD4+ DC subset (Finkelman et al., 1996) and later for the
CD8α+ DC subset by DEC205 (CD205) antibody (Hawiger et al.,
2001).
As a third possibility intravenous injection of soluble antigens
reach thymic and splenic DCs, which are then presented under
steady state conditions with half-lives between 3 and 22 h (Muller
et al., 1993). Soluble protein injections such as myelin antigens
may reach preferentially the CD4+ CD11b+ DCs and can lead to
protection from autoimmunity (Li et al., 2008). Injected apoptotic
cells as a source for tolerogenic antigens are capturedby spleenDCs
and may represent promising tolerogenic tools in allogeneic trans-
plantation settings (Steinman et al., 2000; Morelli and Larregina,
2010).
It is of note that s.c. injection of immature DCs leads to their
upregulation of costimulatory molecules and a loss of tolerogenic-
ity (Fu et al., 1996). TNF-matured DCs that were tolerogenic when
injected i.v., turn into highly immunogenic DCs when applied
the s.c. route (Voigtländer et al., 2006). This may indicate that
tissue injury mediated maturation by ex vivo isolation proce-
dures or via the s.c. injection route causes danger signals strong
enough to abrogate tolerogenicity of immature DCs. Recently,
human autologous monocyte-derived DCs, treated with antisense
oligonucleotides against CD40, CD80, and CD86 but not loaded
with speciﬁc antigens were injected intradermally into type 1 dia-
betes patients (Giannoukakis et al., 2011). Although these DCs
were not further characterized, not even on the stability of the
costimulation blockade, they appeared save for the patients but
also without clinical beneﬁt. Thus, DC injections or in vivo target-
ing may prefer the i.v. route or require speciﬁc treatments to gain
maturation resistance.
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MATURE DCs
Mature DCs or, as we proposed earlier, rather fully mature DCs
(Lutz and Schuler, 2002), are inducers of effector T cell responses
by their costimulation, homing, and cytokine production capaci-
ties and therefore candidates for anti-microbial or tumor vaccine
approaches (Steinman, 2008). Further “licensing” of DCs through
CD40 signals leads to elevated cytokine secretion and resistance
to Treg-mediated loss of costimulatory molecules on mature DCs
(Hänig and Lutz, 2008; and references therein). However, although
immature DCs are more efﬁcient in Treg de novo induction from
naive T cells, mature DCs have been demonstrated to act superior
in activating the suppressor function of Tregs. Details on the role
of DC costimulation for Treg generation and function has been
reviewed elsewhere (Pletinckx et al., 2011a).
SEMI-MATURE DCs
Partial maturation resulting in upregulation of MHC and cos-
timulatory molecules and lymph node homing capacity but
lack of proinﬂammatory cytokine production was termed semi-
maturation (Lutz and Schuler, 2002). An advantage of semi-
mature tolerogenic DCs over immature tolerogenic DCs is their
lymph node homing potential by which DCs can reach T cells
at their anatomical locations. Although under debate, to create
the term “semi-maturation” allowed the collection of arguments
for or against it and then to keep or discard it. So far, further
experimental evidences for the phenotype and tolerogenic poten-
tial of semi-mature DC stages have been obtained and reviewed
(Mills and McGuirk, 2004; Morelli et al., 2005; Braun et al., 2006;
Nouri-Shirazi and Thomson, 2006; Rutella et al., 2006; van Duiv-
envoorde et al., 2006; Young et al., 2007; Frick et al., 2010; Morel
and Turner, 2011). Recently, gene-expression proﬁling of different
semi-mature DCs (TNF,Trypanosoma antigens) was compared to
fully mature DCs (LPS) and revealed mainly quantitative differ-
ences between these DC types. A common signature of only 24
proinﬂammatory genes characterized the semi-mature DC types
with a total of 160–466 genes regulated as opposed to almost 5000
genes regulated by LPS (Pletinckx et al., 2011b). These data under-
line that besides the qualitative instruction of pathogen- versus
self-antigen-recognition by triggering or not of pattern recogni-
tion receptors alsomoreﬁne-tunedquantitative differences in gene
regulation seem to determine DC tolerogenicity versus immuno-
genicity (Figure 1). Here, some speciﬁc aspects of semi-mature
tolerogenicity will be discussed.
TOLEROGENICITY OF SEMI-MATURE DCs
Initial ﬁndings in the mouse, that TNF-matured bone-marrow-
derived DCs (TNF/DCs) and intravenously injected into mice
could act tolerogenic (Menges et al., 2002) were similar to ﬁndings
that cross-tolerance of CD8+ T cells in vitro induced by human
DCs also required TNF stimulation (Albert et al., 2001). Repetitive
injections of peptide-loadedTNF/DCs intomice allowed complete
protection from experimental autoimmune encephalomyelitis
(EAE). The resultingT cell responsewas characterized by a lowered
IFN-γ production, absence of IL-4, and increased IL-10 produc-
tion of CD4+ T cells as detected by ELISA (Menges et al., 2002).
Thus, a tolerogenic response being compatible with induction of
a regulatory T cell type 1 (Tr1)(Roncarolo et al., 2006). Similar
observations have beenmadewith TNF/DCs in amurine thyroidi-
tis model (Verginis et al., 2005),DNA-matured DCs in experimen-
tal collagen-induced arthritis (Jaen et al., 2009), MyD88-silenced,
and then LPS-matured DCs in rat intestinal allograft transplan-
tation (Yang et al., 2011). Others generated semi-mature DCs
by dexamethasone and 1α,25-dihydroxyvitamin D3 (VD3) treat-
ment alone (Unger et al., 2009) or in parallel with LPS exposure
FIGURE 1 | Semi-maturation as a quantitative level of gene regulation
in DC maturation. DC maturation and the subsequent induction of
polarizedTh1 or Th2 responses has been considered mostly as a
consequence of qualitative differing maturation pathways, meaning the
microbial direction of either Th1- or Th2-inducing genes in DCs with
simultaneous down-regulation of tolerance genes (Quality Model). Indeed,
the Notch ligands Jagged-2 and Delta-4 characterize the different DC
types. In parallel, quantitative differences appear for Th1- or Th2-polarizing
DCs (Quantity Model). DC that reach only a semi-mature stage with
various stimuli and induceTh2 cells are characterized by a low number of
regulated proinﬂammatory genes and only few hundred genes more in
total. In contrast, the same proinﬂammatory genes are induced in
Th1-polarizing fully mature DCs but almost 5000 genes in total. Thus,
semi-maturation can be observed also by the number of regulated genes.
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of cells that were protective in collagen-induced arthritis model
(Stoop et al., 2010). Semi-mature DCs generated by sequential
dexamethasone and LPS treatment were superior to immature
DCs to prolong allograft survival in mice (Emmer et al., 2006).
In a murine graft versus Of note, in macaques a tolerogenic DC
semi-maturation stage seems to be achieved by using bone mar-
row as a source but not peripheral blood monocytes (Moreau
et al., 2008). When human monocyte-derived DCs were gener-
ated in GM-CSF, IL-4, TGF-β, and IL-10 for 7 days the resulting
regulatory immature DCs could respond to TNF only by par-
tial upregulation of costimulatory molecules as compared to DCs
cultured without TGF-β and IL-10 (Sato et al., 2003a). Unfor-
tunately, their cytokine production, CCR7 expression or homing
potential was not tested and the murine counterparts generated
from bone marrow appeared rather immature, although success-
ful in the treatment of graft-versus-host disease model (Sato et al.,
2003a,b).
A recent study tested the clinical potential of different human
monocyte-derived semi-mature DCs, considering also CCR7-
dependent homing potential and maturation stability (Boks et al.,
2012). Human immature monocyte-derived DCs were compared
with DCs that received additional treatments of dexamethasone,
rapamycin, TGF-β, or IL-10. The results indicated that the treat-
ments with the inhibitors for 1 h, revealed immature DCs without
migration capacity, while following cocktail maturation (TNF,
IL-1β, PGE2) allowed the acquisition of migratory capacity on
CCL21 in vitro and maturation resistance to further TLR expo-
sure. However, it appeared that IL-10, the strongest inhibitor of
DC maturation and the best Treg inducer, also showed the poor-
est migration, indicating that a balanced inhibition/maturation
protocol will be essential for successful application of semi-
mature DC in the clinic. Together, weak maturation stimuli alone
or combinations of suppressive treatments followed by matu-
ration stimuli leads to partial DC maturation with tolerogenic
capacity.
ROLE OF REPETITIVE SEMI-MATURE DC INJECTIONS
After establishing that repetitive injections of TNF/DCs lead to Tr1
cell generation (Menges et al., 2002) additional studies in our lab
indicated that thismight be a result of chronicTh2 immunity.After
peptide restimulation of spleen cells from IL-4R deﬁcient mice in
the EAE protection model IL-4 production by ELISA (and in addi-
tion IL-13) was detectable (Wiethe et al., 2008), indicating that
low amounts of IL-4 were produced in wild-type mice but con-
sumed completely and therefore not detectable. Intracellular ﬂow
cytometry showed that bothCD4+ T cells andNKT cells recognize
peptide or glycolipid antigens presented by TNF/DCs leading to
their IL-4 and IL-13 production. More detailed investigations on
CD1d presentation by TNF/DCs identiﬁed both type I and II NKT
cells to secrete these cytokines (Wiethe et al., 2007). A further aug-
mented activation of so-called non-classical or type II NKT cells,
i.e.,CD1d-restricted and glycolipid-recognizingCD4+ T cells with
a diverse TCR repertoire (Godfrey et al., 2004),was observed when
the co-inhibitory molecule B7-H1/PD-L1 was absent on the DCs
(Brandl et al., 2010). Thus, repetitive TNF/DC injections induce
IL-10, little IL-4, and IL-13 production of conventional CD4+
T cells (Figure 2), together with IL-4, IL-13, but not IL-10, by
invariant type I NKT cells as well as by non-classical type II NKT
cells.
Recent analyses showed that a single stimulation of T cells by
TNF/DCs induced a Th2-like proﬁle in vitro and in vivo (Plet-
inckx et al., 2011b), that allows immune deviation of antigen-
speciﬁc T cells away from pathogenic Th1 and Th17 responses
in EAE. Only repetition leads to dominant Tr1-mediated con-
trol of EAE. We also tested whether this mixed Th2/Tr1 response
would inﬂuence asthma as a Th2 disease model. The data revealed
that TNF/DCs could neither boost nor protect Th2-mediated
asthma in mice, presumably pointing to a neutral effect of Th2-
booster together with Tr1-suppression (Pletinckx et al., 2011b).
This is different to what has been described by others with
intranasally applied OVA allergen also leading to Tr1 cells without
additional Th2 induction and protecting from asthma (Akbari
et al., 2001). These differences in the clinical outcome may
however, also be explained by IL-10 production by the endoge-
nous lung DCs after intranasal asthma therapy, which was not
observed with our adoptively transferred TNF/DCs. Alternatively,
a local control of the disease in lung lymph nodes (Akbari
et al., 2001) rather than systemically injected TNF/DCs, reach-
ing the spleen, may be beneﬁcial in the asthma model. Together,
semi-mature DC-induced mixed Th2/Tr1 responses can pro-
tect from Th1/Th17-induced (Sato et al., 2003a) diseases but
pure Tr1 induction will be necessary to treat also Th2-mediated
diseases.
INFLAMMATION, PATHOGENS, COMMENSALS, AND TUMORS AS
INDUCERS OF SEMI-MATURATION
There is accumulating evidence that typical Th2-inducing
pathogens also induce only partial DC maturation such as shown
for Leishmania amazonensis (Prina et al., 2004), Bordetella per-
tussis (Vojtova et al., 2006), cholera toxin (Bimczok et al., 2007),
Nippostrongylus brasiliensis (Balic et al., 2004), or Echinococcus
multilocularis (Nono et al., 2012). As a consequence the resulting
Th2 response will be dominated by Tr1 cells due to the chronic-
ity of the infection (O’Garra et al., 2004) and was similar as
observed for repetitive injections of TNF/DCs in the autoim-
mune models mentioned above. In addition, commensals such as
Lactobacillus rhammnosus (Veckman et al., 2004) or Bacteroides
vulgatus (Frick et al., 2006) but also exogenous noxes such as
nicotine (Hu et al., 2012) or endogenous inﬂammasome trig-
gers such as ATP (Ben Addi et al., 2008) can induce partial DC
maturation.
Receptors that mediate semi-maturation include both TNFR1
and TNFR2 (Funk et al., 2000), IL-6R (Frick et al., 2010), aller-
gen targeting to FcγR I (Hulse and Woodfolk, 2008) but also
Trypanosoma brucei-derived VSG antigens with presumably low
afﬁnities for MyD88-dependent Toll-like receptors (TLR; Plet-
inckx et al., 2011b). Treatment of human patients with psoriasis
and multiple sclerosis by fumaric acid similarly induces a Th2-
inducing DC type (Ghoreschi et al., 2011). In sum, inﬂammatory
mediators, commensal bacteria, or typical Th2-pathogens can
induce DC semi-maturation. This may indicate that commen-
sals and pathogens exploit “this is only an inﬂammation” signaling
pathways in DCs to escape strong immunity and elimination but
also immunopathology (MacDonald and Maizels, 2008).
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FIGURE 2 |Two distinct DC semi-maturation pathways induce different
types of regulatoryT cells. Immature tissue-resident DCs or in vitro
generated BM-DCs that are triggered through theWnt/β-catenin pathway or
proinﬂammatory cytokines become semi-mature DC with migratory potential
to T cell areas. Upon induction of IL-10 production by the DCs as observed via
intranasal antigen application Tr1 cell generation from naiveT cells is favored.
Alternatively, repetitive injections of IL-10-deﬁcient semi-mature DC also lead
to Tr1 cell generation. Different, only incompletely understood maturation
pathways activate tissue-resident DC into RelB/p52+ semi-mature DCs
homing to theT cell areas of peripheral lymph nodes. Transport of soluble and
cell-associated antigens have been observed for ssmDCs. By usingTGF-β and
retinoic acid naive T cells are converted into Foxp3+ Tregs by ssmDCs.
It has been shown that a mild DC activation can occur through
disrupting DC–DC contacts formed by homotypic interaction via
E-cadherin and this dissociation is indeed accompanied by partial
maturation of the DCs through theWnt/β-catenin signaling path-
way (Jiang et al., 2007). These disrupted DCs upregulated MHC II
and costimulatory molecules but did not secrete proinﬂammatory
cytokines. When pulsed with myelin antigen they induced IL-10
producing T cells that controlled EAE (Jiang et al., 2007) using the
same protocol and reaching very similar results as demonstrated
by our group with TNF/DCs before (Menges et al., 2002). In a col-
itis model Wnt signals activating β-catenin in DCs were required
to control the disease, indicative for a tolerogenic DC activation
(Manicassamy et al., 2010). However, so far it remains unclear
whether DCs matured along the β-catenin pathway are resistant to
further stimulation that would be demanding for therapeutic use.
Finally, in humanpatients suffering frompancreatic ductal ade-
nocarcinoma or chronic pancreatitis conventional DCs and pDCs
isolated from the peripheral blood appeared at a semi-mature stage
with impaired stimulatory function on T cells (Tjomsland et al.,
2010). Similarly, DC inﬁltrating tumors of non-small cell lung
cancer patients appeared immature or semi-mature or remained
semi-mature when exposed to maturation stimuli (Perrot et al.,
2007). Further investigations have to elucidate whether such DCs
are actively tolerogenic.
LIMITATIONS OF SEMI-MATURE DC TOLEROGENICITY
As already mentioned above injections of semi-mature DCs pro-
tected from Th1/Th17 immunity in the EAE model but not
in Th2-mediated asthma (Pletinckx et al., 2011b). In addition,
TNF/DC application for EAE therapy, i.e., after EAE induction,
failed (our unpublished observations). The reasons for this failure,
however, are obvious. In the preventive setting a large part of the
auto-antigen-speciﬁc naive CD4+ T cell repertoire is primed and
polarized into Th2 and subsequently into Tr1 phenotypes. If EAE
induction follows by immunization with the same auto-antigenic
peptide, the frequency of the remaining auto-antigen-speciﬁc
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naive CD4+ T cells is insufﬁcient to generate enough pathogenic
Th1 and Th17 cells. This is the principle of tolerance induction by
immune deviation. Reversely, if most auto-antigen-speciﬁc cells
are polarized into Th1 or Th17 cells by the EAE protocol, it is
difﬁcult at later time points to generate enough protective Th2 or
Tr1 cells from the remaining antigen-speciﬁc T cell pool. Thus,
tolerance induction by immune deviation or induced Tregs/Tr1
cells relies on sufﬁcient numbers of naive auto-antigen-speciﬁc T
cells at the time of therapy.
In a type I diabetes model TNF/DCs loaded with an auto-
antigenic peptide on MHC class I molecules also failed to act
tolerogenic on CD8+ T cell autoimmunity (Kleindienst et al.,
2005), indicating that the DC semi-maturation may not allow
tolerization of high afﬁnity CD8+ T cells such as the OT-I trans-
genic T cells used in this system. Furthermore, dose-dependent
effects have been observed in collagen-induced arthritis, where
semi-matureDCs injected at low amounts were protectivewhereas
high amounts failed to do so (Lim et al., 2009).
As for immature DCs also the stability of the semi-mature phe-
notype is important to maintain tolerogenicity and for this the
injection route may play an essential role. While three i.v. injec-
tions of TNF/DCs were completely protective in the EAE model,
s.c. application of the same DCs was deleterious and all mice died
from severe EAE. One reason was a remaining responsiveness of
TNF/DCs to further maturation signals such as LPS in vitro, which
led to IL-12 production. In vivo, TNF/DCs injected s.c. homed to
the draining lymph node but appeared cytokine negative unlike
endogenous DCs, which showed proinﬂammatory cytokine pro-
duction (Voigtländer et al., 2006). This indicates that s.c. injection
abrogates semi-mature DC tolerogenicity, in part by interactions
with other DCs. In cancer patients, only s.c. or intralymphatic
but not i.v. injections of DCs matured with tumor antigens could
prime Th1 responses, while T cell activation was observed under
all conditions (Fong et al., 2001), but tolerogenic parameters were
not analyzed for the i.v. settings. Interestingly, intracerebral injec-
tions of TNF/DCs inmice still could act tolerogenic (Zozulya et al.,
2009).
As mentioned above, it will be necessary to establish semi-
mature DCs that remain stable, and this might be achieved by
subsequent treatment with a maturation inhibitor followed by a
maturation inducer (Sato et al., 2003a; Boks et al., 2012).
STEADY STATE MIGRATORY DCs
IN VIVO COUNTERPARTS OF IN VITRO GENERATED SEMI-MATURE DCs?
After all, the question remained whether semi-mature stages of
DCs can be detected in vivo andwhether they also exert tolerogenic
functions. Early observations indicated that the afferent lymph
contained “veiled cells” representing DCs with dendrites as a sign
of their maturity (reviewed in (Lutz and Schuler, 2002). Later it
has been shown that peripheral lymph nodes of mice contained
a fraction of DCs that expressed high levels of MHC II and the
costimulatory molecules CD80, CD86, and CD40 on their sur-
face (Ruedl et al., 2000; Henri et al., 2001). Another remarkable
similarity of these lymph node DCs was their endocytosis capac-
ity despite the mature cell surface marker proﬁle (Ruedl et al.,
2001), indicative for an incomplete maturation. These partially
mature DCs exclusively represent the immigrated steady state
migratory fraction of formerly skin-resident DCs. Their migra-
tion through the lymphatics depends on CCR7 expression like for
pathogen-induced migratory DCs (Ohl et al., 2004). They consist
of three major subsets, identiﬁed as epidermal Langerhans cells
(LCs), dermal Langerin+, and dermal Langerin− DC subtypes
(Romani et al., 2010), although even more subsets or functional
states may exist (Henri et al., 2010). Also the intestine contains
CCR7-dependent state migratory DCs (ssmDCs) but they appear
less mature after arrival in mesenteric lymph nodes as compared
with their skin migratory counterparts (Worbs et al., 2006). The
reasons for this are unclear.
Analyses in pigs revealed that their skin-draining lymph nodes
contained ssmDC and they appear at a semi-mature state (Bertho
et al., 2011). Human tonsils contain a mature DC fraction (Sum-
mers et al., 2001) but it remains to be shown that these cells are
not resident DCs matured by inﬂammatory processes since ton-
sils lack connection to afferent lymphatics and surgical removal of
tonsils (which enable such studies) are indicated only after chronic
inﬂammations. Analyses of human peripheral lymph nodes from
tumor-free melanoma patients, and thereby considered as steady
state lymph nodes, contained two subsets of skin-derived CD1a+
CD11cint LCs and CD1a+ CD11chigh dermal DCs (van de Ven
et al., 2011). Both subsets expressed more CD80, CD86 CD40, and
CD83 as compared to their resident counterparts. Despite their
more mature phenotype, these DCs produced lower amounts of
proinﬂammatory cytokines and were weaker in priming T cell
responses, indicative for primarily tolerogenic functions. Super-
natants of human tumor cell lines (Kuang et al., 2008) could
induce partial DC maturation in vivo, similar to what has been
observed in pancreatic adenocarcinomas (Tjomsland et al., 2010)
and non-small cell lung cancers (Perrot et al., 2007) where such
cells accumulated in the tumor tissue.
Together, ssmDCs of the skin-draining lymph nodes in mice,
pigs, and humans DCs display a semi-mature phenotype by
expressing higher costimulatorymolecules and having the homing
capacity to lymph nodes.
TOLEROGENIC FUNCTIONS OF ssmDCs
It became evident from early studies that ssmDCs transport self-
antigens to the draining lymph nodes (Huang et al., 2000; Hemmi
et al., 2001), but the consequences for T cells by the presentation of
these antigens were still open, although tolerance induction was
proposed. Subcutaneously implanted osmotic minipumps indi-
cated that Foxp3+ Tregs could be de novo converted by this type
of constant low dose soluble antigen delivery (Apostolou and von
Boehmer, 2004). Later we could show that this low dose solu-
ble antigen delivery by the pump system requires RelB+/p52+
CCR7+ ssmDCs (Azukizawa et al., 2011). Since pump implan-
tation requires a surgical intervention, this system may not fully
represent steady state conditions, despite equivalent induction of
Tregs. Direct comparison of soluble antigen delivery via subcuta-
neousminipumpswith cell-associated transgenic neo-self-antigen
expression of OVA in the epidermis (K5-mOVA mice), revealed
the same dependency on ssmDCs with the same kinetics and fre-
quency of CD4+ Treg induction (Azukizawa et al., 2011; Figure 2)
or CD8+ T cell depletion (Waithman et al., 2007). Recent data
suggest that ssmDCs may control the whole pool of homeostatic
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lymph node T cell circulation by producing VEGF that stimulated
formation of high endothelial venules (HEVs) to enable T cell
entry and stimulated ﬁbroblastic reticular cells to secrete CCL21
that acts chemotactic for T cells (Wendland et al., 2011). Thus,
ssmDCs control T cell homeostasis in peripheral lymph nodes
and act tolerogenic on CD4+ and CD8+ T cells, unlike TNF/DCs.
It is however unclear to date what distinguishes these ssmDCs
in the mentioned self-antigen model systems that induced IL-10−
Foxp3+ Tregs from ssmDCs that captured exogenous OVA or Bor-
detella ﬂagellin that was applied intranasally and induced IL-10+
Foxp3− Tr1 cells (Akbari et al., 2001; McGuirk et al., 2002). One
possibility could be that tolerogenic immune evasion strategies
of bacterial ﬂagellin or low doses of endotoxin attached to OVA
may lead to IL-10 release by the DCs, which is not observed under
completely pathogen-free conditions.
IN VIVO TARGETING OF ssmDCs FOR TOLERANCE INDUCTION
The existence of ssmDCs, which bear lymph node homing poten-
tial, are partially mature but still tolerogenic, offer their clinical
exploitation by speciﬁc targeting. In fact earlier studies may have
targeted ssmDCs for tolerance induction in an unscheduled man-
ner.We found thatDEC205 is expressed at higher levels on ssmDCs
than lymphnode resident or splenicDCs (ownunpublished obser-
vations). Therefore antigen-targeting to this marker by i.v. injec-
tion may also or even preferentially target ssmDC in peripheral
lymph nodes (Hawiger et al., 2001; Kretschmer et al., 2005).
An alternative route to reach ssmDCs is via epicutaneous anti-
gen application. Plaster-mediated delivery of self-antigenic myelin
peptide was able to prevent EAE induction (Bynoe et al., 2003;
Szczepanik et al., 2005). Although not further investigated, it
is likely that ssmDCs have been the vehicle to induce myelin-
speciﬁc Tregs in the skin-draining lymph nodes. Surprisingly, even
approaches using gene gun delivery of antigens, that has been
developed for immunogenic vaccines, may be used to induce sta-
ble tolerance by induction of Foxp3+ Tregs and this may occur
through ssmDCs (Ettinger et al., 2012).
This principle of targeting ssmDCs through the skin may also
account for tolerogenic strategies in allergy treatment (Werfel,
2009; Senti et al., 2011). Such treatment showed therapeutic suc-
cess in murine allergy models using OVA, pollen, house dust
mite, or peanut as allergens (Mondoulet et al., 2010, 2011, 2012;
Dioszeghy et al., 2011). First clinical studies using epicutaneous
immunotherapy in childhood cow milk allergy patients demon-
strated safety although the threemonths of treatment didnot reach
therapeutic success (Dupont et al., 2010). The reversal of an exist-
ing allergy may need extended periods of treatment as suggested
from other studies in patients with pollen allergy that showed
a moderate beneﬁt (Senti et al., 2009, 2010). Alternatively, the
intranasal application route may be superior to the skin and also
employs partially mature migratory DCs and led to Tr1 induction
in the pulmonary lymph nodes (Akbari et al., 2001).
Finally, the potential success of such epicutaneous or transcuta-
neous tolerance strategiesmay be encouraged by the fact that some
pathogens hitchhike ssmDCs for immune evasion. A prominent
example is HIV, which infects peripheral immature DCs resident
in the skin or mucosa and then awaits to be transported to the
draining lymphnodes for further infection of CD4+ T cells as their
major targets, and even converting some of these into HIV-speciﬁc
Tregs (Smed-Sorensen and Lore, 2011). Together, semi-mature
DCs as represented by ssmDCs may prove valuable targets for clin-
ical epicutaneous or transcutaneous tolerance induction protocols
in the future.
SEMI-MATURE pDCs
So far this review concentrated on conventional/myeloid semi-
mature DC or ssmDCs. However, this does not exclude the exis-
tence of semi-mature stages also for pDCs. The biology of pDCs is
very different as compared to conventional DCs but certainly they
have in common to present antigens to T cells in tolerogenic or
immunogenic fashions.
Recent data indicate that pDCs infected in vitro with HIV may
be modiﬁed by the virus to reach a semi-mature stage that facil-
itates Treg induction (Smed-Sorensen and Lore, 2011). Similar
observations have been made with tumor-inﬁltrating pDCs that
show impaired maturation potential but without providing T cell
assays (Perrot et al., 2007; Tjomsland et al., 2010). In contrast,
freshly isolated pDC from mice also appeared semi-mature, but
pulsed with Leishmania antigen and reinjected into mice showed a
protective effect, indicative for their immunogenic activity (Remer
et al., 2007).
Together, more detailed analyses for pDCs are required to
evaluate a therapeutic potential of semi-mature pDCs.
CONCLUSION
The initially surprising ﬁnding that partially matured DCs can
still act tolerogenic has now reached a broader base by numer-
ous reports and more mechanistic insights. Semi-mature DCs can
be generated in vitro and exert a distinct spectrum of tolero-
genicity after injection. The ﬁnding that semi-mature ssmDCs
are continuously engaged to tolerize lymph node T cells against
peripheral self-antigens opens further perspectives for therapies,
especially against autoimmune diseases and allergies. Thus, tolero-
genic regimens employing semi-mature DCs may in the future
either be concentrated on in vivo targeting with antibodies or
transcutaneous antigen application regimens.
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